Higher risk of Bell's Palsy after Sinovac's COVID-19 vaccine — study | Inquirer News

Higher risk of Bell’s Palsy after Sinovac’s COVID-19 vaccine — study

/ 10:15 AM August 17, 2021

 A healthcare worker prepares a dose of China's Sinovac Biotech vaccine for the coronavirus disease (COVID-19) in Jakarta, Indonesia, March 5, 2021.

FILE PHOTO: A healthcare worker prepares a dose of China’s Sinovac Biotech vaccine for the coronavirus disease in Jakarta, Indonesia, March 5, 2021. REUTERS/Willy Kurniawan

Risk of Bell’s Palsy, a type of facial paralysis, is higher after the first dose of Sinovac Biotech Ltd’s COVID-19 vaccine CoronaVac, according to a study published in The Lancet Infectious Diseases journal.

“The beneficial and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of this generally self-limiting adverse event,” the study mentioned.

Article continues after this advertisement

The study conducted in more than 451,000 individuals showed 28 clinically confirmed cases of Bell’s Palsy following CoronaVac, compared to 16 cases following Pfizer/BioNtech’s vaccine.

FEATURED STORIES

“Our findings suggest an overall increased risk of Bell’s palsy after CoronaVac vaccination,” according to the study.

The study performed in Hong Kong assessed the risk of the adverse event within 42 days following vaccination.

Article continues after this advertisement

Sinovac did not immediately respond to a request for a comment.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Sinovac, The Lancet

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.